These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 4550256

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy.
    Simmons RL, Rios A.
    Natl Cancer Inst Monogr; 1973 Dec; 39():57-68. PubMed ID: 4595327
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Neuraminidase treated cells and their role in cancer immunotherapy.
    Simmons RL, Rios A.
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
    Simmons RL, Rios A.
    Johns Hopkins Med J Suppl; 1974 Mar; 3():75-84. PubMed ID: 4536589
    [No Abstract] [Full Text] [Related]

  • 8. Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice.
    Vaage J.
    Cancer Res; 1972 Feb; 32(2):193-9. PubMed ID: 5058179
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunoprophylaxis of transplantable methylcholanthrene-induced murine fibrosarcomas by immunization with embryo cells expressing endogenous murine leukemia virus antigens.
    Zbar B, Manohar V, Sugimoto T, Ashley MP, Kato Y, Rappaport P.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4499-507. PubMed ID: 6272979
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
    Yron I, Weiss DW, Robinson E, Cohen D, Adelberg MG, Mekori T, Haber M.
    Natl Cancer Inst Monogr; 1973 Dec; 39():33-55. PubMed ID: 4362523
    [No Abstract] [Full Text] [Related]

  • 16. Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
    Spence RJ, Simon RM, Baker AR.
    J Natl Cancer Inst; 1978 Feb; 60(2):451-9. PubMed ID: 621758
    [Abstract] [Full Text] [Related]

  • 17. Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue.
    Vaage J.
    Cancer Res; 1971 Nov; 31(11):1655-62. PubMed ID: 5121668
    [No Abstract] [Full Text] [Related]

  • 18. Effect of different cancer treatment methods on immunity to an antigenic transplantable murine fibrosarcoma (Meth A).
    Khafagy M, Wanebo HJ, Alfieri A, Hahn EW.
    AJR Am J Roentgenol; 1977 Jun; 128(6):1027-9. PubMed ID: 414534
    [No Abstract] [Full Text] [Related]

  • 19. Regression of established methylcholanthrene tumors by intratumor injections of Vbrio cholerae neuraminidase.
    Simmons RL, Rios A, Ray PK.
    J Surg Oncol; 1972 Jun; 4(4):298-305. PubMed ID: 5083567
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.